Sarepta Therapeutics (SRPT) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright
May 7, 2018 8:17 AM EDTH.C. Wainwright raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $90.00) while maintaining a Buy rating following the company's 1Q. During its 1Q18 corporate update, Sarepta also disclosed an exclusive collaboration and investment in Myonexus Therapeutics.
The alliance,... More
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
May 7, 2018 6:20 AM EDTNeedham & Company raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $109.00 (from $75.00) while maintaining a Buy rating.
Analsyt Chad Messer commented, "Sarepta reported in line 1Q:18 Exondys revenues of $64.6M. Exondys received a negative trend vote in the EU, for which Sarepta... More
Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
May 4, 2018 8:50 AM EDTRBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $98.00 (from $91.00) while maintaining an Outperform rating.
Analyst Rick Bienkowski commented, "On the back of solid 1Q Exondys 51 sales reaffirming confidence in 2018 revenues and future DMD franchise growth, and increasing enthusiasm into June's... More
